NONOF - Eli Lilly weight loss drug outperforms Novo Nordisk's in real-world study
2023-11-28 08:17:10 ET
More on Eli Lilly
- Eli Lilly: Perfectly Priced Healthcare Giant
- Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise
- Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript)
- M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey
- Eli Lilly confirms plans to build $2.5B site in Germany
For further details see:
Eli Lilly weight loss drug outperforms Novo Nordisk’s in real-world study